News Releases

Wednesday, October 22, 2014

UH Case Medical Center’s REHEARSAAAL trial testing clinical performance in virtual environment

CLEVELAND – Practice makes perfect.
 
University Hospitals (UH) Case Medical Center and Simbionix recently launched a multi-center, randomized study comparing the clinical performance of abdominal aortic aneurysm (AAA) procedures with and without prior rehearsal in a virtual environment for physicians.
 
The study investigates the clinical related performance and cost analysis of AAA procedures performed using standard protocols compared to procedures performed with prior rehearsal. A total of 11 sites across the country are enrolling up to 150 patients who have chosen to have elective endovascular AAA repair.
 
UH Case Medical Center’s Henry Baele, MD, Vascular Surgeon and Assistant Professor of Surgery at Case Western Reserve University School of Medicine, is leading the trial and is optimistic about the system’s potential.


Wednesday, October 22, 2014

Local researchers helping lead national study evaluating new approach that could slow progression of Alzheimer’s disease

CLEVELAND – University Hospitals (UH) Case Medical Center is participating in a new national Alzheimer’s disease (AD) clinical research study evaluating the potential benefits of an investigational medicine when taken by people with mild-to-moderate AD who are already being treated with donepezil (Aricept). Titled NOBLE, the trial is evaluating an investigational drug, T-817MA, which may have the potential to modify the pace of the disease in those who are currently suffering with mild-to-moderate AD.
 
The advent of NOBLE comes at a time when the AD clinical research community is moving to prevention-oriented trials that do not include people already diagnosed with the disease.  An estimated five million people in the United States already suffer from mild-to-moderate AD, with those numbers growing at an alarming rate. However, no new drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD since 2003. The NOBLE study was launched to potentially help address this gap in treatment.


Thursday, October 16, 2014

UH Infection Control: Ebola Preparedness Plan is in Place

If a person suspected of having Ebola were to seek care at a University Hospitals facility, UH is prepared. That's the message from Amy Ray, MD, MPH, an infectious disease specialist who has chaired the University Hospitals System Infection Control Committee since 2008.

"If a patient presents for care, we are prepared to deliver safe care. We will continue to remain vigilant to identify patients at risk, at or before the point of care, and provide our health care personnel with the optimal personal protective equipment," she says. "Given global travel, it is within the realm of possibility that a patient may seek care at our facilities."



Tuesday, October 07, 2014

Foundation Fighting Blindness and Harrington Discovery Institute partner to accelerate drug development for critical causes of blindness

Columbia, MD/Cleveland, OH – The Foundation Fighting Blindness in Columbia, MD, and Harrington Discovery Institute in Cleveland, OH, announce a new nationwide initiative, “The Gund-Harrington National Initiative for Fighting Blindness,” focused on finding treatments and cures for people affected by inherited retinal diseases that lead to blindness. More than 10 million Americans, and many more times that number worldwide, of every age and race suffer vision loss from this type of eye disease.

“It is a great honor to team up on a shared mission with the Gordon and Lulie Gund family, the Foundation Fighting Blindness and University Hospitals,” said Ron Harrington, who along with his wife, Nancy; daughter, Jill; and son and daughter-in-law, Ron and Lydia, made a gift of $50 million in 2012 to launch the Harrington Discovery Institute. “It is deeply meaningful for our family to share Gordon and Lulie Gund’s longtime philanthropic mission and passion.” 


Thursday, September 25, 2014

New research outlines promising therapies for small cell lung cancer

CLEVELAND –  Two recently published studies by a research team at University Hospitals (UH) Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and “is a disease in urgent need of new drug therapies,” write the study’s authors.
 
“In small cell lung cancer, which impacts about 30-40,000 people each year in the United States, there has been no therapeutic progress and very little research,” says Afshin Dowlati, MD, lead author and Director of the Center for Cancer Drug Development at UH Seidman Cancer Center. “Additionally, there are no approved targeted therapies for the disease. These studies lay the foundation for future research aimed at finding important new treatments for this highly malignant cancer.”
 
A study titled, RET Mutation and Expression in Small Cell Lung Cancer, was published in the September issue of Journal of Thoracic Oncology and found a new mutation in SCLC which may play a role in the disease’s development. The researchers found that the genetic mutation, called RET (rearranged during transfection), was linked to rapid cell growth.



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.